GSK, Ris-Rez, Risvutatug Rezetecan, Small Cell Lung Cancer, ES-SCLC, B7-H3, Antibody-Drug Conjugate, ADC, Phase Ib Trial, Phase III Clinical Trial, EMBOLD Study, Oncology Research

London, United Kingdom, October 18, 2026 GSK has announced the first global clinical data for risvutatug rezetecan (Ris-Rez), its...